Ortho Evra contraceptive transdermal birth control patch label update

Ortho Women?s Health & Urology, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., has updated the prescribing information for ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system) to include further epidemiologic data. – The U.S. Food and Drug Administration (FDA) approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that users of the birth control patch were at higher risk of developing serious blood clots, also known as venous thromboembolism (VTE), than women using birth control pills. VTE can lead to pulmonary embolism.

Combined hormone therapy increases lobular breast cancer risk

Fred Hutchinson Cancer Research Center leads first study designed to evaluate the association between combined HRT use and the risk of lobular breast cancers. – Postmenopausal women who take combined estrogen/progestin hormone-replacement therapy for three years or more face a fourfold increased risk of developing various forms of lobular breast cancer, according to new findings by researchers.

Osteoarthritis risk linked to shorter index finger

University of Nottingham researchers revealed that people whose index finger is shorter than their ring finger are at higher risk of osteoarthritis. – People whose index finger is shorter than their ring finger are at higher risk of osteoarthritis, a new University of Nottingham study has found.

Women with osteoporosis have increased long-term risk for new fracture

Older women with a prevalent vertebral fracture should be treated for osteoporosis irrespective of bone mineral density BMD. – Over a 15 year period, women with low bone mineral density and a previous vertebral fracture had an increased risk of a new vertebral fracture compared to women with normal bone mineral density and no previous fracture, according to a study in the December 19 issue of JAMA.